Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management.

The system – which already has a breakthrough device designation from the FDA – will take the form of a small patch-like device similar to Abbott's FreeStyle Libre 3 device (pictured above ...

Abbott (NYSE:ABT) is launching a new initiative that takes a look at some of the stigmas and stereotypes that come with ...

The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the consensus estimates of $11.01 billion and ...

The FreeStyle Libre 3 system helped Nathan manage his diabetes. Now, he's sharing his story to help lift stigma.Abbott NORTHAMPTON, MA / ACCESS Newswire / February 7, 2025 / As a competitive powerlift ...

One cupcake won't kill you,' 'I'm going to get diabetes just looking at that,' 'That person doesn't look like they have ...

5 Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device to empower people in improving overall health and wellness.

The FreeStyle Libre 3 system helped Nathan manage his diabetes. Now, he's sharing his story to help lift stigma. Abbott NORTHAMPTON, MA / ACCESS Newswire / February 7, 2025 / As a competitive ...

Abbott continues to pioneer ground-breaking technology to support people living with diabetes. The company revolutionized diabetes care 10 years ago with its world-leading FreeStyle Libre ...

New survey shows 40% of people living with diabetes have skipped or missed a doctor's appointment due to shame or stigma 1 70% of people with diabetes said supportive comments from others can ...